With Positive Data From Ionis, Angelman Syndrome Race Intensifies

 
• By Jessica Merrill

Ionis plans to initiate a Phase III trial for ION582 in the first half of 2025, positioning it just behind Ultragenyx in the race to bring a treatment to market for the rare neurologic condition.

Progress is being made in the treatment of Angelman syndrome • Source: Shutterstock

More from Neurological

More from Therapy Areas